Date Title Description PDF
24 Jun 2024 On business and financial situation ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth Download
08 May 2024 On P&L The Company releases the press release related to the first three months of 2024 financial results Download
08 May 2024 On P&L The Company releases the first three months 2024 financial results presentation Download
25 Apr 2024 On business and financial situation ROVI announces agreement to manufacture pre-filled syringes Download
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download

Pages

Date Title Description PDF
21 Oct 2021 Liquidity and counterparty agreements Download
21 Oct 2021 On business and financial situation The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). Download
07 Oct 2021 Liquidity and counterparty agreements Download
04 Oct 2021 Liquidity and counterparty agreements Download
01 Sep 2021 On business and financial situation ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages